Encyclopedia of Psychopharmacology

2015 Edition
| Editors: Ian P. Stolerman, Lawrence H. Price

Schizotypal Personality Disorder

  • Nobumi Miyake
  • Seiya Miyamoto
Reference work entry
DOI: https://doi.org/10.1007/978-3-642-36172-2_7012


Borderline schizophrenia; Latent schizophrenia; Schizotaxia; Schizotype; Schizotypy; SPD; STPD


In DSM-5 (American Psychiatric Association 2013), schizotypal personality disorder (SPD) is characterized by pervasive social and interpersonal deficits and by subtle, psychotic-like symptoms (Table 1).
Schizotypal Personality Disorder, Table 1

Classification and criteria of schizotypal personality disorder according to DSM-V (American Psychiatric Association 2013)

Diagnostic criteria 301.22 (F21)

A. A pervasive pattern of social and interpersonal deficits marked by acute discomfort with, and reduced capacity for, close relationships as well as by cognitive or perceptual distortions and eccentricities of behavior, beginning in early adulthood and present in a variety of contexts, as indicated by five (or more) of the following

 1. Ideas of reference (excluding delusions of reference)

 2. Odd beliefs or magical thinking that influences behavior and is inconsistent with...

This is a preview of subscription content, log in to check access.


  1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, pp 655–659Google Scholar
  2. Hazlett EA, Goldstein KE, Kolaitis JC (2012) A review of structural MRI and diffusion tensor imaging in schizotypal personality disorder. Curr Psychiatry Rep 14(1):70–78PubMedCentralPubMedGoogle Scholar
  3. Herpertz SC, Zanarini M, Schulz CS et al (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8(4):212–244PubMedGoogle Scholar
  4. Hori A (1998) Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 52(1):13–19PubMedGoogle Scholar
  5. Keshavan M, Shad M, Soloff P et al (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 71(1):97–101PubMedGoogle Scholar
  6. Koenigsberg HW, Reynolds D, Goodman M et al (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64(6):628–634PubMedGoogle Scholar
  7. Ripoll LH, Triebwasser J, Siever LJ (2011) Evidence-based pharmacotherapy for personality disorders. Int J Neuropsychopharmacol 14(9):1257–1288PubMedGoogle Scholar
  8. Siever LJ, Koenigsberg HW, Harvey P et al (2002) Cognitive and brain function in schizotypal personality disorder. Schizophr Res 54(1–2):157–167PubMedGoogle Scholar
  9. Tarbox SI, Pogue-Geile MF (2011) A multivariate perspective on schizotypy and familial association with schizophrenia: a review. Clin Psychol Rev 31(7):1169–1182PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Schizophrenia Treatment Center, Department of NeuropsychiatrySt. Marianna University School of MedicineKawasakiJapan